Zhijie Wang

List of Publications by Year
in descending order

80 papers	3,821 citations	185998 28 h-index	138251 58 g-index
88 all docs	88 docs citations	88 times ranked	5610 citing authors

#	ARTICLE	IF	CITATIONS
1	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21083-21088.	3.3	396
2	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 2019, 5, 696.	3.4	380
3	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
4	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology, 2020, 6, 375.	3.4	215
5	Influence of Chemotherapy on <i>EGFR</i> Mutation Status Among Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3077-3083.	0.8	188
6	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer. JAMA Oncology, 2021, 7, 709.	3.4	185
7	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. Cancer Research, 2018, 78, 6486-6496.	0.4	176
8	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respiratory Medicine,the, 2018, 6, 681-690.	5.2	166
9	TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 146-154.	1.6	166
10	Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. PLoS ONE, 2014, 9, e110780.	1.1	121
11	Lung Cancer in People's Republic of China. Journal of Thoracic Oncology, 2020, 15, 1567-1576.	0.5	114
12	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. Cancer Research, 2019, 79, 7-20.	0.4	113
13	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
14	Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e54170.	1.1	89
15	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget, 2016, 7, 20810-20824.	0.8	73
16	Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncology, 2020, 6, 631.	3.4	70
17	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. Clinical Cancer Research, 2019, 25, 5049-5060.	3.2	66
18	Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. Journal of Thoracic Oncology, 2020, 15, 556-567.	0.5	66

#	Article	IF	Citations
19	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology, 2021, 16, 1099-1117.	0.5	64
20	The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1209-1219.	3.3	56
21	Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling. Clinical Cancer Research, 2018, 24, 2100-2109.	3.2	53
22	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Journal of Thoracic Oncology, 2017, 12, 1766-1778.	0.5	51
23	Hypoxia‐inducible factor‐1α and nuclear factor‐ĸB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells. Cancer Science, 2019, 110, 1665-1675.	1.7	50
24	EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer. Oncology, 2012, 83, 248-256.	0.9	43
25	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387.	0.5	39
26	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI. Thoracic Cancer, 2012, 3, 334-340.	0.8	36
27	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2013770.	2.8	34
28	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. Thoracic Cancer, 2021, 12, 66-78.	0.8	32
29	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9990-9995.	3.3	31
30	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Lung Cancer, 2020, 147, 259-268.	0.9	31
31	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
32	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
33	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. Npj Precision Oncology, 2020, 4, 32.	2.3	27
34	MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. Molecular Diagnosis and Therapy, 2022, 26, 203-227.	1.6	23
35	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. Journal of Thoracic Oncology, 2020, 15, 1857-1870.	0.5	19
36	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. Cancer Letters, 2019, 440-441, 180-188.	3.2	15

#	Article	IF	Citations
37	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine, 2020, 18, 232.	2.3	15
38	TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110384.	1.4	15
39	Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. Oncology Letters, 2017, 13, 2425-2431.	0.8	14
40	High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies. Thoracic Cancer, 2016, 7, 100-110.	0.8	12
41	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non‐small cell lung cancers. Science Advances, 2021, 7, .	4.7	12
42	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Medicine, 2021, 19, 239.	2.3	11
43	Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer. Thoracic Cancer, 2018, 9, 805-813.	0.8	10
44	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. Thoracic Cancer, 2018, 9, 1166-1173.	0.8	10
45	Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs. Thoracic Cancer, 2020, 11, 3501-3509.	0.8	9
46	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	0.8	9
47	<p>Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors</p>. Cancer Management and Research, 2020, Volume 12, 7151-7164.	0.9	8
48	Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma. Thoracic Cancer, 2020, 11, 1149-1159.	0.8	8
49	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1‐SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 527750.	2.2	7
50	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 3888-3901.	1.3	7
51	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	1.3	6
52	*PAPPA2* mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer. Cell Proliferation, 2022, 55, .	2.4	5
53	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.. Journal of Clinical Oncology, 2021, 39, 8522-8522.	0.8	4
54	Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology, 2022, 40, 9028-9028.	0.8	4

#	Article	IF	Citations
55	Real world study of the continuation of bevacizumab beyond disease progression after first‑line treatment containing bevacizumab in Chinese patients with advanced non‑small cell lung cancer. Thoracic Cancer, 2018, 9, 1716-1724.	0.8	3
56	The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. Journal of Cancer, 2020, 11, 3106-3113.	1.2	3
57	Bevacizumab combined with pemetrexed successfully treated lung adenocarcinoma complicated with pulmonary tumor thrombotic microangiopathy: a case report and literature review. Annals of Palliative Medicine, 2021, 10, 767-777.	0.5	3
58	Pegylated recombinant human granulocyte colony‑stimulating factor regulates the immune status of patients with small cell lung cancer. Thoracic Cancer, 2020, 11, 713-722.	0.8	3
59	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. Journal of the National Cancer Center, 2021, 1, 153-162.	3.0	3
60	Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays. Translational Lung Cancer Research, 2021, 10, 4336-4352.	1.3	3
61	Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 801741.	1.5	3
62	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer. JAMA Oncology, 2020, 6, 932.	3.4	2
63	Evaluation of radical surgical treatment in the management of 58 locally advanced rectal neuroendocrine neoplasms, one multicenter retrospective study. European Journal of Surgical Oncology, 2021, 47, 3166-3174.	0.5	2
64	Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.. Journal of Clinical Oncology, 2018, 36, 3024-3024.	0.8	1
65	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 12-8.	0.7	1
66	Establishment of prognostic nomograms for predicting the progression free survival of <scp>EGFR</scp>‑sensitizing mutation, advanced lung cancer patients treated with <scp>EGFR‑TKIs</scp>. Thoracic Cancer, 2022, 13, 1289-1298.	0.8	1
67	A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma. Translational Lung Cancer Research, 2020, 9, 833-836.	1.3	0
68	Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply. JAMA Oncology, 2020, 6, 1116.	3.4	0
69	In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy. Journal of Thoracic Oncology, 2020, 15, e72-e73.	0.5	0
70	Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.. Journal of Clinical Oncology, 2021, 39, e21002-e21002.	0.8	0
71	Abstract 1614: The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer. , 2021, , .		0
72	Associations between mutations of DNA damage response and prognosis in microsatellite instability prevalent tumors.. Journal of Clinical Oncology, 2018, 36, e24257-e24257.	0.8	0

#	Article	IF	Citations
73	The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy.. Journal of Clinical Oncology, 2018, 36, e15007-e15007.	0.8	0
74	Phase I study of apatinib combined with docetaxel in *EGFR*-negative advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, e21184-e21184.	0.8	0
75	Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.. Journal of Clinical Oncology, 2018, 36, 12034-12034.	0.8	0
76	Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e13528-e13528.	0.8	0
77	Nab-PTX and nab-PTX combined with immune checkpoint inhibitors for relapsed small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 8576-8576.	0.8	0
78	Blockade of STAT3/IL-4 overcomes EGFR T790M-*cis*-L792F-induced resistance to osimertinib via promoting M2 macrophages polarization.. Journal of Clinical Oncology, 2022, 40, e20552-e20552.	0.8	0
79	Maximum somatic allele frequency-adjusted blood-based tumor mutational burden balances the effect of intratumor heterogeneity on response to immune checkpoint Inhibitors in non-small cell lung cancer patients.. Journal of Clinical Oncology, 2022, 40, e21137-e21137.	0.8	0
80	*PAPPA2* mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC and SKCM.. Journal of Clinical Oncology, 2022, 40, 2617-2617.	0.8	0